Discriminative Stimulus Effects of Putative Antipsychotic Drugs by Lekander, Alex
Northern Michigan University
NMU Commons
All NMU Master's Theses Student Works
7-2019
Discriminative Stimulus Effects of Putative
Antipsychotic Drugs
Alex Lekander
alekande@nmu.edu
Follow this and additional works at: https://commons.nmu.edu/theses
Part of the Animal Studies Commons, Behavior and Behavior Mechanisms Commons, and the
Experimental Analysis of Behavior Commons
This Open Access is brought to you for free and open access by the Student Works at NMU Commons. It has been accepted for inclusion in All NMU
Master's Theses by an authorized administrator of NMU Commons. For more information, please contact kmcdonou@nmu.edu,bsarjean@nmu.edu.
Recommended Citation
Lekander, Alex, "Discriminative Stimulus Effects of Putative Antipsychotic Drugs" (2019). All NMU Master's Theses. 601.
https://commons.nmu.edu/theses/601
 
 
 
 
Discriminative Stimulus Effects of Putative Antipsychotic Drugs 
 
 
By 
 
 
Alex D. Lekander 
 
 
 
 
 
 
 
 
 
 
THESIS 
 
 
Submitted to 
Northern Michigan University 
In partial fulfillment of the requirements 
For the degree of  
 
 
MASTERS OF SCIENCE 
 
 
Office of Graduate Education and Research 
07/2019 
 
 
 
 
 
 
 
 SIGNATURE APPROVAL FORM 
 
TITLE: Discriminative Stimulus Effects of Putative Antipsychotic Drugs 
 
This thesis by Alex D. Lekander is recommended for approval by the student’s Thesis 
Committee and Department Head in the Department of Psychological Science and by the Dean 
of Graduate Education and Research. 
 
 
 
__________________________________________________________ 
Committee Chair: Dr. Adam Prus Date 
 
 
__________________________________________________________ 
First Reader: Dr. Joshua Carlson Date 
 
 
__________________________________________________________ 
Second Reader (if required): Dr. Joseph Porter Date 
 
 
__________________________________________________________ 
Department Head: Dr. Adam Prus Date 
 
 
__________________________________________________________ 
Dr. Lisa Schade Eckert Date 
Dean of Graduate Education and Research
 i 
ABSTRACT 
DISCRIMINATIVE STIMULUS EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS 
By 
Alex D. Lekander 
This study attempted to further explore the discriminative stimulus properties of antipsychotic 
drugs, by establishing the typical antipsychotic drug chlorpromazine, and the atypical 
antipsychotic drug clozapine as discriminative stimulus in two different groups of rats. The rats 
trained to discriminate chlorpromazine from vehicle failed to do so reliably, however nine of ten 
rats trained to discriminate 1.25 mg/kg clozapine from vehicle were able to acquire the 
discrimination in 19.1 sessions. The clozapine cue partially generalized (63.13% drug lever 
responding [SEM = ± 18.91]) to the antimalarial drug methylene blue at the 7.5 mg/kg dose, but 
not to the antimalarial quinacrine. This study found that the antimalarial drug methylene blue 
may share some pharmacological similarities or subjective effects with that of clozapine, and 
further studies into its antipsychotic value, if any, should be explored. 
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INTRODUCTION 
Schizophrenia 
 Schizophrenia is a mental disorder that consists of dysfunction in thought processes and 
emotional regulation, and occurs in roughly 1% of the population (Simeone, Ward, Rotella, 
Collins, and Windisch, 2015). Schizophrenia is characterized by its symptomology. An 
individual may experience delusions, hallucinations, disorganized speech, and abnormal motor 
activity. These particular symptoms are referred to as positive symptoms, indicating that they are 
present. There are also negative symptoms, which indicate a lack of presence, such as social and 
emotional withdrawal, lack of motor response, and avolition (American Psychiatric Association, 
2013).   
History of Psychosis and Schizophrenia 
 Psychosis has been described in various texts from early in human history. The first 
known description of psychosis was found in religious scriptures of India around 1400 B.C.E., 
characterized by confusion and lack of self-control, but differed from confusion due to use of 
physiologically and psychoactive substances, or manic-depressive illness (Gottesman, 1991). 
Under the unitary theory of psychosis, all psychosis was considered symptomology of the same 
underlying spectrum of mental illness until 1889, when Emil Kraepelin was the first to formally 
characterize schizophrenia, which he referred to as dementia praecox, meaning precocial 
dementia. Kraepelin described dementia praecox as a combination of other conditions: catatonia; 
hebrephrenia; and dementia paranoia. This was also the first time that the disease was 
characterized to have a specific neuroanatomical pathology (Adityanjee, Aderibigbe, 
Theodoridis, & Vieweg 1999; Lavretsky, 2008). Kraepelin was among the first to differentiate 
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manic depressive illness and dementia praecox, which, while both shared similar symptomology, 
manic depressive illness main symptoms revolved around disordered mood, while dementia 
praecox symptoms were functional and social disability (Lavretsky, 2008). It was in 1911 when 
Eugene Bleuler first used the term schizophrenia, meaning “split mind”. While Kraepelin 
believed that schizophrenia had a neurological pathology, Bleuler believed that it had a 
psychological pathology, and characterized schizophrenia by fundamental symptoms, common 
to all schizophrenia subtypes: cognitive disturbances; affective blunting; and ambivalence, and 
associative symptoms: hallucinations; delusions; and catatonia (Adiyanjee, et al., 1999; 
Lavretsky, 2008). 
 Kurt Schneider was one of the first researchers to look at schizophrenia longitudinally, 
and took issue with the definition of schizophrenia created by Kraepelin and Bleuler. Their 
definition could provide a diagnosis that was sometimes based on the psychological symptoms, 
and sometimes based on the progression of the disease, while Schneider’s research showed that 
the course of the disease had a general sequence of clinical states, and should be diagnosed by 
the symptoms, as well as the progression (Hoenig, 1983). Schneider’s list of symptoms would 
help improve interrater reliability of diagnosing schizophrenia, and his contributions are still 
used in diagnostic criteria today (Adiyanjee, et al., 1999). 
Neurotransmitters Involved in Schizophrenia 
The exact causes of schizophrenia remain unknown, although there are several 
neurotransmitters that are associated with the disease state (Lavretsky, 2008). Dopamine has 
been implicated to be associated with schizophrenia soon after discovery of antipsychotic drugs 
(APDs). Positron emission tomography (PET) and single photon computerized tomography 
(SPECT) scans of the brains of drug naïve individuals with schizophrenia have shown that there 
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is an increase in dopamine D2 receptors in the striatum, as well as a decrease in the receptor 
affinity for D2, with these differences becoming more pronounced with age (Laruelle, 1998). 
Other studies have found that changes in density of dopamine D1 receptors in the prefrontal 
cortex that may be associated with the negative symptoms and cognitive deficits associated with 
schizophrenia (Howes & Kaspur, 2009).  
Serotonin is another neurotransmitter implicated in the pathology of schizophrenia, which 
has been implicated since the discovery that the hallucinogenic drug, LSD, is a serotonin agonist 
(Lavretsky, 2009; Harrison, 1999). Some research has found evidence of excessive serotonin 
receptors in the anterior cingulate cortex, and the dorsolateral frontal lobe in the brains of 
individuals with schizophrenia (Gurevich & Joyce, 1997; Eggers, 2013). Additionally, many of 
the drugs used for the treatment of schizophrenia have a high affinity for serotonin receptors as 
antagonists and have demonstrated reduction in positive symptoms, and to a lesser effect, 
negative symptoms (Lavretsky, 2009). However, many of these drugs have action on multiple 
receptor sites, and antipsychotic efficacy may be a result of multiple mechanisms of action. 
Glutamate is one of the primary excitatory neurotransmitters of vertebrate brains, which 
accounts for a majority of the synaptic connections in the brain (Meldrum, 2000). Drugs that 
cause dysfunction of glutamate transmission, such as PCP, ketamine, and MK-801, have been 
found to cause psychosis in humans, and cognitive impairments that resemble negative 
symptoms in preclinical models (van der Staay, Rutten, Erb, & Blokland, 2011). Glutamate binds 
to several receptor sites in the brain, such as the NMDA receptors. These receptors have been 
found to be dysfunctional in pre and post synaptic sites in individuals with schizophrenia 
(Moghaddam and Javitt, 2012). While in the dopamine model of schizophrenia, deficits are 
usually limited to the dorsolateral prefrontal cortex, and the striatum; the glutamate model of 
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schizophrenia shows deficits throughout cortical and subcortical brain regions (Javitt, 2009; 
Moghaddam and Javitt, 2012). 
 There are multiple neurotransmitters in dysfunction in the schizophrenic brain. 
Consequently, the most effective treatments for schizophrenia have been drugs that have 
multiple mechanisms of action. APDs are the primary treatment for schizophrenia. APDs fall 
into two different sub-classes: typical APDs, also known as first generation APDs; and atypical 
APDs, also known as second generation APDs. 
The First Drug Treatments for Schizophrenia 
Chlorpromazine is the first APD that was marketed for the treatment of schizophrenia. 
After the drug was developed in 1950, it was first used in combination with morphine to reduce 
the usage of an anesthetizer during surgery, where it was discovered that patients that had been 
treated with chlorpromazine experienced less preoperative and postoperative anxiety (Swazey, 
1972). Chlorpromazine was found to have anxiolytic, antispasmodic, sedative, and antiemetic 
properties, which made it a useful as a surgical drug. Researchers would later discover its use in 
reducing agitation in individuals suffering from manic episodes (Swazey, 1972; Lopez-Monoz, 
et al. 2005). 
Prior to the use of APDs, attempted pharmacological treatments for many mental 
illnesses such as schizophrenia included compounds that were often supported by mainly 
anecdotal accounts, and seldom addressed the core symptoms of the disorder. Treatments 
included use of barbiturates on belligerent patients during manic or otherwise agitated episodes 
to induce sleep; and hypoglycemic shock therapy, in which patients were given injections of 
insulin to induce diabetic coma, which could be reversed by glucose syrup. In addition to 
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hypoglycemic shock therapy, electroshock therapy was also used (Anderson, 2016). When the 
antipsychotic actions of chlorpromazine was first discovered, it brought on the development of 
several similar drugs, which were later characterized by their high binding affinity as antagonists 
to the dopamine D2 receptors (Lehmann and Ban, 1997; Seeman, 2010). The use of 
chlorpromazine and other first generation ADPs were also found to cause movement disorders, 
known as extrapyramidal symptoms (EPS). These side effects include muscle spasms (dystonia); 
tremors, or jerky movements (tardive dyskinesia); restlessness (akathisisa); and general slowness 
of movement (bradykinesia) (Lieberman et al. 2005). Most of these movement disorders would 
appear rather quickly as a patient takes the drug, however tardive dyskinesia, a condition 
characterized by involuntary movements of the face and body, was only seen after being treated 
for several years, and continues even after the drug is terminated (Anderson, 2016). 
When clozapine was first developed in 1959, it was found to have very similar 
neuroleptic effects to that of chlorpromazine, yet did not show the same involuntary movements 
that were thought at the time to be an unavoidable component of APD treatment, which is why it 
later became referred to as an atypical antipsychotic (Crilly, 2007). While atypical APDs can 
cause these extrapyramidal symptoms, they do so with far less frequency than typical 
antipsychotics. With select drugs, this may be due to their high binding affinity for the dopamine 
D2 receptors (Kapur and Remington, 2001). However, there are several atypical antipsychotics 
that do have high binding affinity for dopamine that do not exhibit these symptoms with the 
same frequency as the first generation antipsychotics. Research has suggested instead, that the 
reason ADPs show less extrapyramidal symptoms is due to their complex receptor binding 
profiles (Meltzer, 2004). Although, atypical APDs are less likely to cause movement disorders, 
they often carry risk of weight gain, new-onset type II diabetes, and metabolic dysfunction 
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(Baptista, Kin, Beaulieu, and de Baptista, 2002). Clozapine, like many other atypical 
antipsychotics, has a higher binding affinity to several serotonin receptors, in addition to affinity 
for dopaminergic, histaminic, adrenergic, and cholinergic receptors. (Goudie, Cooper, Cole, and 
Sumnall, 2007).  
Chlorpromazine, in addition to many other typical APDs, is derived from the organic 
compound phenothiazine, which has a history in the development of a number of different drugs 
(Lopez-Monoz, et. al 2005). The first phenothiazine compound synthesized was methylene blue, 
which had originally been used as a textile dye, before the discovery of its antimalarial properties 
(Shen, 1999). In addition to methylene blue, there are many other compounds derived from 
phenothiazine that have medical uses, aside from antipsychotics, yet are no longer used due to 
their low therapeutic window. These compounds have been used as antihistamines (promazine; 
promethazine), trypanocidals (trypan red), antihelmintics (phenothiazine), and antiparkinsonians 
(diethazine) (Swayze, 1972). With such slight variations in the chemical structure of these 
phenothiazine based compounds, they have shown a wide variety of uses in medicine over the 
years. 
The discovery of antipsychotics has improved the lives of those afflicted with mental 
illness, yet it still comes at a great financial cost. People with schizophrenia deal with direct costs 
of: hospitalization; follow up treatment; care givers; and drugs, as well as indirect costs related to 
loss of productivity due to managing their symptoms. In the United States, the direct and indirect 
costs of the disease have been growing steadily over the past years (Tajima-Pozo, de Castro 
Oller, Lewczuk, and Montanes-Rada, 2015), with direct and indirect costs totaling over $62.7 
billion as of 2002, with about 8% of that total being the cost of drugs (McEvoy, 2007). In the 
areas developing world, making older, typical APDs available in the place of atypicals can 
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significantly lower the cost of treatment, as well as repurposing old drugs that may have 
antipsychotic efficacy (Chisholm, et al. 2008).  
Before the Discovery of Chlorpromazine 
 While there are many drugs that are currently available for the treatment of 
schizophrenia, the cost may be especially high for those in the developing world (Chisholm, et 
al., 2008). Some preclinical trials have shown that there are other, more cost effective drugs that 
may work in place of current APDs (Goudie, et al., 2007), and that there are many similar 
compounds that have therapeutic value for a variety of ailments (Swayze, 1972). While the 
results may be modest, there are many other antihistamines and phenothiazine compounds that 
could be evaluated for their therapeutic effects in the treatment of schizophrenia and other 
psychotic disorders. 
 Methylene blue is a phenothiazine compound that was originally used as a dye in textiles, 
and became the first fully synthetic drug used in medicine (Howland, 2016). Methylene blue was 
found effective in treating the symptoms of malaria, in addition to having several other medicinal 
uses (Healy, 2002), such as reducing the symptoms of manic depressive psychosis (Narsapur, 
and Naylor, 1983). More recently, it has been found to have some anxiolytic and antidepressant 
effects (Eroglu, and Caglayan, 1997).  Due to the calming and anxiolytic effects that methylene 
blue may share with other phenothiazine compounds, such as chlorpromazine, there may be 
some value in evaluating it against current APDs. 
 Several other phenothiazine derived drugs are still currently used in medicine, mostly in 
the treatment of malaria, but also used as antiprotozoals, and antihelmintics, such as quinacrine. 
While quinacrine is quite similar in structure to methylene blue and chlorpromazine, it does not 
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share many of their sedative or agitation reducing features. Antimalarials that share features with 
quinine, in that they cause many psychiatric features similar to psychosis and cognitive deficits 
(Nevin & Croft, 2016). Quinacrine has also been shown to decrease sensitivity to prepulse 
inhibition (PPI) testing in rats, similar to that of patients with schizophrenia, who have issues 
with sensorimotor gating (Lee, Farooqui, Dawe, Burgunder, & Ong, 2009). Quinacrine would 
likely be able to serve as a negative control for a comparison to the subjective effects of APDs 
against other drugs in the antimalarial class. 
Drug Discrimination 
 Drug discrimination is an operant conditioning procedure in which an organism is trained 
to discriminate between the subjective effects of a drug from the solution in which it is delivered, 
known as the vehicle. When using non-human animals for this procedure in an operant chamber, 
the animal is taught to respond a certain way after given a drug in order to receive a 
reinforcement, usually food. When the animal feels the subjective effects of the drug, it knows to 
respond by pressing the drug appropriate lever to receive food, and when the animal is given the 
vehicle that serves as the placebo, it will respond by pressing the non-drug lever for 
reinforcement. Once an animal is trained to respond to the subjective effects of one drug, the 
animal is then given novel drugs to examine if they will respond in a similar way while under the 
subjective effects of the novel drug. If they respond in a similar manner, it may be likely that the 
two drugs have similar pharmacological activity (Young, James, and Rosencrans, 2009). In this 
way, drug discrimination assays can be used as a tool to determine the mechanisms of action of 
novel drugs. 
 The panoply of receptor actions by clozapine, as noted earlier, appear to engender a 
compound discriminative cue as studied in a drug discrimination procedure (Kelley & Porter, 
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1997; Prus, et al., 2016). When looking at other drugs that have a similar compound cue, it was 
found that the antihistamine cyproheptadine had a similar binding profile to clozapine. When 
these drugs were evaluated for their subjective effects in a drug discrimination trial, a dose of 
cyproheptadine at 40 mg/kg fully substituted for a dose of clozapine in rats at 5 mg/kg (Kelley & 
Porter, 1997; Goudie, et al. 2007). Although, this was a preclinical study, showing similarity of 
these drugs in rats, it shows that drugs with similar receptor binding profiles can have similar 
effects. 
 Several studies have established chlorpromazine as a discriminative cue in rats (Stewart, 
1962; Overton, 1982; Porter et al., 1998; Porter et al., 2004). Porter et al. (1999) successfully 
trained six rats to discriminate a 1.0 mg/kg IP dose of chlorpromazine from its vehicle in a two 
lever discrimination task. When the rats were tested against various APDs, the atypical APDs 
clozapine and olanzapine, fully substituted for chlorpromazine, as well as the typical APD 
thioridazine, while the atypical antipsychotic raclopride, and typical antipsychotic haloperidol 
only partially substituted for chlorpromazine, showing the chlorpromazine does share 
discriminative stimulus properties with some atypical and typical APDs (Porter et al., 1999).  
Clozapine has also been shown to be able to be able to form a discriminative cue 
(Goudie, & Taylor, 1998; Porter, Varvel, Vaan, Philibin, & Wise, 2000; Porter, et al., 2005; Prus, 
et al., 2005; Porter, & Prus, 2009). Prus et al. (2005) had trained nine rats to discriminate 5.0 
mg/kg of clozapine from vehicle in a two lever discrimination task. The atypical antipsychotics 
olanzapine, quetiapine, and ziprasidone, as well as the typical APDs thioridazine fully 
substituted for clozapine, while there was partial substitution for the atypical APDs risperidone, 
and sertindole, while typical antipsychotics chlorpromazine, fluphenazine, and haloperidol did 
not substitute for clozapine. While many typical antipsychotics have been found to generalize to 
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chlorpromazine (Porter, et al., 1999), and many atypicals have been found to generalize to 
clozapine (Prus, et al. 2005), there has been less research looking at completely novel drugs with 
calming properties to see how they generalize to current APDs that are available. 
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RATIONALE 
 It has been close to 70 years since the discovery of chlorpromazine, and the therapeutic 
effects of modern ADPs have not made substantial gains in therapeutic efficacy. Therefore, an 
investigation into early compounds with putative APD-like effects is warranted. In particular, 
few studies have re-evaluated such compounds in direct comparison to established APDs in 
assays with strong predictive validity for determining mechanism of action, such as the drug 
discrimination procedure. Current APDs can be evaluated for their subjective effects through the 
use of drug discrimination procedures. The purpose of the present study is to evaluate the 
subjective effects of the antimalarial drugs methylene blue and quinacrine, which are known to 
have similarity in chemical structure, in rats trained to discriminate the APDs chlorpromazine, 
and clozapine to see if the test drugs show similarity in their subjective effects to that of the 
current APDs by way of stimulus generalization. If these drugs do generalize to current 
antipsychotic medication, it may indicate that there is therapeutic value in further evaluating 
these drugs as antipsychotic alternatives.  
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MATERIALS AND METHODS 
Animals 
 Twenty male Sprague-Dawley rats were used for this study. Ten of which were trained to 
discriminate chlorpromazine at 1.0 mg/kg from vehicle (Group 1), and the other ten of which 
were trained to discriminate clozapine at 1.25 mg/kg from vehicle (Group 2). The rats were 
individually housed in a temperature and humidity controlled room, on a 12 hour light to dark 
cycle, with the lights on from 5:00 AM to 5:00 PM. Rats were put on restricted feeding to 
achieve 85% free feeding weight. Water was available ad-lib in their home cages. Rats were fed 
following daily sessions that occurred around the same time every day. 
Apparatus 
 Eight standard rat operant chambers were used (ENV-008-VP, MED Associates, St. 
Albans, VT) contained in sound attenuating cabinets for this study (ENV-018MD, MED 
Associates, St. Albans, VT). Cabinets were equipped with fans for masking noise and 
ventilation, and all equipment was controlled by MED-PC IV software. The operant chambers 
(30 cm long × 24 cm wide × 29 cm high) were constructed of a Plexiglas top and side door 
panels, and other walls and components made of stainless steel. A concealed light bulb located 
near the top of the operant chamber provided illumination during all training and test sessions. 
Two retractable levers (drug and vehicle levers) were located on either side of a food hopper 
centered on the stainless steel wall of the chamber. Food reinforcement consisted of 45 mg food 
pellets (Dustless Precision Pellets, Rodent Grain-Based Diet, Bio-Serv, Flemington, NJ) 
 
 
 13 
Drugs 
 Generalization testing was conducted with chlorpromazine hydrochloride (0.0625; 0.125; 
0.5; 1.0; 2.0; and 4.0 mg/kg), clozapine (0.15625; 0.3125; 0.625; 1.25; 2.5; and 5.0 mg/kg); 
methylene blue – tetramethylthionine chloride (7.5; 15.0; 30.0; and 60.0 mg/kg); quinacrine 
dihydrochloride (1.0; 10.0; and 30.0 mg/kg) All drug doses were based on previous literature (Al 
Asmari, Al Sadoon, Obaid, Yesunayagam; & Tariq, 2017; Overton, 1982; Porter, et al., 1999; ; 
Porter, Varvel, Vann, Philibin, & Wise, 2000; Oz, Lorke, Hasan, & Petroianu, 2011). All drugs 
will be purchased from Sigma-Aldrich, St. Loius, MO, except clozapine which was purchased 
from Ascent Scientific, Bristol, UK. The salt form of chlorpromazine, methylene blue, and 
quinacrine was used, while the base form of clozapine was used. All drugs were dissolved in 
water with a few drops of lactic acid and sodium hydroxide to raise the pH of the solution above 
5.5. All drugs were administered intraperitoneally (IP) at a volume of 1.0 ml/kg of body weight, 
with the exception of chlorpromazine also being administered subcutaneously (SC) after the first 
30 training sessions (see below). All drugs were administered 30 minutes before test sessions 
(Overton, 1982), unless otherwise noted. 
Magazine Training 
 Rats were placed in the operant chamber in which food was delivered to them every 60 
seconds (fixed time 60), with no levers available. This was intended to train the rats to associate 
the sound of the food hopper with the availability food reward. This occurred over one session. 
Lever Press Training 
 During lever press training, the center lever was available, while the left and right levers 
were retracted, as they were used later when they were paired with the drug and vehicle. For 
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every lever press the rat makes, it was given a food pellet as a reinforcement (Fixed Ratio-1). 
The session concluded when the rat received 30 food pellets, or when 15 minutes elapsed. As the 
rats learned the lever pressing behavior, the fixed ratio to receive the food reinforcement was 
increased until the rats reliably lever pressed 30 times to receive a food pellet (Fixed ratio-30). 
Single Lever Training 
 During single lever training, the rats were be given an intraperitoneal (IP) injection of 
either their respective training drug, 1.0 mg/kg chlorpromazine for group 1, and 1.25 mg/kg 
clozapine the group 2, or vehicle (consisting of deionized water with a few drops of lactic acid 
and sodium hydroxide) in it thirty minutes prior to their training session. The rats had one of the 
left or right levers assigned to the drug condition and the opposite lever assigned to the vehicle 
condition. The lever assignment was counterbalanced among the rats. The rats were tested on a 
single-double alternating design, on the drug (D), and vehicle (V) for training sessions (D-V-D-
D-V-V-D-V). After the animals successfully received 30 food pellets on an FR-30 for seven of 
the eight sessions, they moved on to discrimination training. 
Two Lever Training 
 During two lever discrimination training, the rats were injected with either their 
respective training drug or vehicle, and presented with the right and left lever both available. The 
two lever training continued to use a single-double alternation design. These trials used an FR-
30, in which if the rat pressed the incorrect lever, the count on the condition-appropriate lever 
would reset, and the rat had to press 30 more times in order to receive a food reinforcement. The 
rats had to complete the following criteria for five of six consecutive sessions: the first 
completed fixed ratio requirement must be on the condition appropriate lever; the rat must have 
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had a response rate of 0.08 responses per second and, and the rat must have completed 80% of 
their responding on the condition appropriate lever during the given session. These conditions 
continued throughout the course of the study to make sure that the rats retain discriminability 
among the conditions.  
 During the course of the two lever training, the group 1 had to undergo several phase 
changes, as during the first 30 sessions, nine out of the ten rats would fail to discriminate each 
session, At session 32, the training dose was increased to 2.0 mg/kg via IP based on the dose 
used by Goas and Boston (1978), however this appeared to make no difference in the ability for 
the rats to discriminate. At session 52, the route of administration was changed from IP to SC, 
but all but two rats were completely rate suppressed by this change. At session 54, the dose was 
lowered to 1.0 mg/kg via SC. The rats were still performing below 5 responses per minute, and 
so at session 62, the dose was lowered to 0.5 mg/kg, as this dose has still found to partially 
substitute for the 1.0 mg/kg dose in previous literature (Porter, et al., 1999). 
Substitution Testing 
 When the rats had successfully completed two training sessions, a test session was given. 
The rat was given one of the test drugs via IP or SC injection, and the rat was put in the operant 
chamber with a two lever choice after waiting for the appropriate pretreatment time for the drug. 
The first FR30 completed on a lever (with a press to the opposite lever resetting the counter) 
resulted in the end of the session. The length of the session depended on how long it took the rat 
to complete an FR-30, or the test session would end when 15 minutes had passed, regardless of 
whether or not they had completed an FR-30. Doses of drugs began with the drug vehicle and 
were subsequently tested in an escalating order.  
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Data Analysis 
 The percent drug lever responding for drug and non-drug levers, the responses per minute 
(RPM), and the lever on which the first FR-30 schedule were completed and recorded for each 
training and test sessions. Percent drug appropriate responding and RPM was reported as means 
and standard error of the mean (SEM) in dose-response curves. Full substitution was defined as 
80% or greater drug appropriate responding; and partial substitution was defined as above 60% 
drug appropriate responding and below 80% drug appropriate responding. As the drug 
discrimination procedure was designed to evaluate the novel compounds for the subjective 
effects of their respective training drugs, the drugs were assessed on whether they met criteria for 
full, partial, or no substitution, as opposed to statistical significance, to determine the percent of 
training drug appropriate responding (Glennon, and Young, 2011). Drugs that produced full 
substitution had the ED50 value calculated for the dose response curve using a least-squares 
linear regression analysis. One factor repeated measures analysis of variance (ANOVA) tests 
were conducted to look at changes in the response rates, with Dunnett’s multiple comparison 
tests conducted to identify significant differences in the changes among the response rates 
between vehicle and each dosage of the drug tested. Rate comparisons were calculated using 
Prism Graphpad 8.1.2 (San Diego, CA). 
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RESULTS 
Group 1: Chlorpromazine Drug Discrimination Training 
 Out of the ten rats trained to discriminate 1.0 mg/kg administered via IP injection 
chlorpromazine from its vehicle, two were able to meet the training criteria. After a month of 
additional training, all ten rats had the dose increased to 2.0 mg/kg via IP injection, in which one 
more rat was able to meet training criteria. Chlorpromazine administration was then changed 
from 30 minutes of pretreatment time to 60 minutes of pretreatment time, which had no effect on 
performance. Many of the rats began to exhibit rate suppressing effects of the 2.0 mg/kg dose, 
but did not do so with consistency, experiencing rate suppression on the drug one day, but not 
the next. The route of administration was subsequently changed from an IP injection to an SC 
injection. All rats began to succumb to rate suppressing effects at this time, so the dose was once 
again lowered to 1.0 mg/kg, administered via SC. The rats continued to experience rate 
suppression at the 1.0 mg/kg dose, so the dose was once again lowered to 0.5 mg/kg via SC 
injection. After being acclimated to the 0.5 mg/kg SC dose, five more rats made discrimination 
criteria. Including the five phase changes, eight of the ten rats made criteria in 55.1 sessions 
(SEM = ± 12.2). Two rats failed to make discrimination criteria and were excluded from the 
study (See Figure 1).  
Group 1: Chlorpromazine Generalization Testing 
 Only one of the eight rats that made criteria had completed the chlorpromazine 
generalization testing, therefore it was not possible to depict a generalization curve based on the 
averages of the drug discrimination testing for this group. 
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Group 2: Clozapine Drug Discrimination Training 
 Out of the 10 rats that were trained to discriminate 1.25 mg/kg clozapine from its vehicle, 
nine rats were able to meet the training criteria within a mean of 19.1 sessions (SEM = ± 2.6). 
One rat failed to meet discrimination criteria and was removed from the study (See Figure 2). 
Group 2: Clozapine Generalization Testing 
 For the nine rats tested clozapine produced full generalization, 80% drug lever 
responding or above, for clozapine at the training dose of 1.25 mg/kg (ED50 = 0.5094 mg/kg). 
Partial generalization, between 60 and 80% drug lever responding, occurred to the 0.3125 mg/kg 
(75.00% [SEM = ± 15.43]), and 2.5 mg/kg doses (76.07% [SEM = ± 14.42]). A significant 
decrease in response rate compared to vehicle occurred at the 5.0 mg/kg dose (F [6, 48] = 4.84, p 
< 0.001) (See Figure 3). 
Group 2: Chlorpromazine Generalization Testing 
 In the four rats tested partial generalization for clozapine occurred with a 2.0 mg/kg 
(78.75% [SEM = ± 22.05]), and 4.0 mg/kg (77.55% [SEM = ± 12.36]) doses of chlorpromazine. 
The tests had also indicated that 3 out of 4 rats had full generalization at the 2.0 mg/kg dose, 
while only two of them exhibited full generalization at the 4.0 mg/kg dose. There was a 
significant difference in responding relative to vehicle chlorpromazine (F [6, 18] = 3.502, p = 
0.0179), however a post-hoc analysis did not reveal differences between each dose and vehicle 
(See Figure 4). 
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Group 2: Methylene Blue Generalization Testing 
 In the five rats tested partial generalization for clozapine occurred at the 7.5 mg/kg 
(63.96%, [SEM = ±18.91]) dose of methylene blue. Among the tests, only one rat displayed full 
generalization at the 7.5 mg/kg dose. There was no significant change in responding relative to 
vehicle at any of the doses of methylene blue (F [3, 12] = 2.125, p = 0.1504). However, rate 
suppression occurred for one rat, and in different rats at each of the three doses that were tested 
(See Figure 5). 
Group 2: Quinacrine Generalization Testing 
 In the three rats tested, quinacrine did not fully or partially substitute for the 1.25 mg/kg 
clozapine training dose, with the highest drug lever responding at the 30 mg/kg dose (43.77% 
[SEM = ± 19.57]). There was no significant change in responding at any of the doses tested (F 
[3, 12] = 1.313, p = 0.3157) (See Figure 6). 
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DISCUSSION 
Group 1: Chlorpromazine Generalization 
 The rats from group one were successfully able to establish chlorpromazine as a 
discriminative stimulus, which is supported by previous literature (Stewart, 1962; Porter, et al., 
1999; Porter, et al., 2005), but only after several phase changes. Eight of ten rats acquired the 
discrimination at a mean 55.1 training sessions at the 0.5 mg/kg SC dose, which was much 
longer that the 29.7 training sessions used by Porter et al. (1999) at the 1.0 mg/kg IP dose. There 
first phase change could have failed due to increasing the time, as opposed to shortening the 
time, as in Overton (1982), in which the pretreatment time for rats given 2.0 and 4.0 mg/kg 
chlorpromazine to discriminate a T-maze was only 20 minutes. This is highly unlikely, as the 
rats could be seen succumbing to the rate suppressing effects of the 2.0 mg/kg via SC of 
chlorpromazine within the first ten minutes of their pretreatment time in the present study.  
The route of administration might have accounted for this. Some drugs that are taken in 
through the digestive system, whether it be orally, or intraperitoneally, may be subject to first 
pass metabolism, and have their active metabolites degrade in the gut or liver before being able 
to exerting their psychoactive effect. Certain drugs are more susceptible to first pass metabolism, 
chlorpromazine has been found to be less stable in plasma concentrations in humans that have 
taken the drug orally, compared to intramuscular (IM) injection (Dahl & Standjord, 1977), which 
shows that the route of administration in administering chlorpromazine can affect biological 
availability. Additionally, chronic administration can be an issue, as an organism may become 
tolerant to drug effects over time. Rats given increasing doses of chlorpromazine over a 40 week 
period have been able to take up to 200 mg/kg via IM (Boyd, 1960), while other studies have 
shown that the lethal dose in 50% of rats (LD50) for chlorpromazine for other routes of 
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administration is 142 mg/kg orally; 75 mg/kg SC; 58 mg/kg IP; and 23 mg/kg IV (Lewis & Sax, 
2004). While Lewis and Sax (2004) did not include the LD50 for IM dosages, 200 mg/kg IM is 
still much higher than even the highest LD50 of chlorpromazine at 142 mg/kg orally. The rats of 
this study tolerating a dose of chlorpromazine at the 2.0 mg/kg level is not very likely, as if they 
had developed a tolerance, they would not likely be able to discriminate at the lower 0.5 mg/kg 
dose. 
There is evidence in the literature for chlorpromazine, among other typical APDs not 
being easily established as a discriminative stimulus. Harris and Balster (1971) were unable to 
get rats to discriminate chlorpromazine at the 1.0 mg/kg via IP dosage in a two lever operant 
chamber. McElroy, Stimmel, and O’Donnell (1978) were able to establish the typical APD 
haloperidol at a discriminative stimulus in rats in a mean of 45 training sessions, while Donahue, 
Webster, Hillhouse, Oliveira, and Porter (2019) were able to establish haloperidol as a 
discriminative stimulus in mice in a mean of about 31 training sessions at the 0.05 mg/kg SC 
dose. However, the mice of this study eventually failed to retrain discriminability. As haloperidol 
has been show to generalize in chlorpromazine trained rats (Porter, et al., 1999), as well 
chlorpromazine being generalized in haloperidol trained rats (McElroy, et al., 1978), indicates 
that these two drugs likely have a similarity in pharmacological action, while Donahue, et al. 
(2019), shows that haloperidol does not display a particularly strong discriminative stimulus, in 
which discriminability may be difficult to maintain. The results may be species, drug, or even 
route of administration specific, however, the previous literature does show there have been 
difficulties establishing typical antipsychotics as discriminative stimuli, and this may be due to a 
failure to retain discriminability, which should be further explored. 
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Another likely factor contributing to the difficulty in establish typical antipsychotics as 
discriminative stimulus is the antagonism of dopamine receptors. Porter et al. (1999), was not 
able to get rats to discriminate 2.0 mg/kg, due to the rats responding below five per minute 
during initial two lever training, which is why the dose was reduced to 1.0 mg/kg. Additionally, 
the study had showed that at the 1.0 and 2.0 mg/kg doses, there was a significant decrease in 
response rate compared to vehicle. Donahue et al. (2019) showed similar results in the 
discrimination of haloperidol in mice. The training dose of 0.05 mg/kg did not any significant 
changes in response rate, the 0.1 and 0.2 mg/kg doses showed significant rate suppression 
compared to that of vehicle. Previous studies were able to establish dosages of chlorpromazine as 
discriminative stimulus as high as 4.0 mg/kg (Overton, 1982; Stewart, 1962), although the 
discrimination procedures in these studies used a shock avoidance discrimination procedure. 
These studies may show that shock avoidance is a more salient reinforcement than a food 
reward, but do not necessarily show that using a higher dose is more salient in discrimination. 
Group 2: Clozapine Generalization 
 The rats from group two were successfully able to establish clozapine as a discriminative 
stimulus, which is supported by previous literature at the 5.0 mg/kg dose (Kelley and Porter, 
1997; Goudie and Taylor, 1998; Prus, et al., 2004; Goudie, et al. 2007), and the 1.25 mg/kg dose 
(Porter, et al., 2000; Prus, et al., 2004; Prus, et al. 2006), which is more selective for atypical 
antipsychotics. Nine out of ten rats were able to acquire the two lever discrimination for the 1.25 
mg/kg dose in a mean of 19.1 training sessions, which is faster than Prus, et al. (2004), which 
had achieved discrimination in about 55 sessions, as well as slightly faster than Porter, et al., 
which achieved discrimination in about 28 sessions. The discriminative stimulus was dose 
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dependent with an ED50 of 0.5094 mg/kg, and full generalization for only the training dose of 
1.25 mg/kg. 
Group 2: Chlorpromazine 
 Chlorpromazine was found to partially substitute for clozapine at the 2.0 and 4.0 mg/kg 
dosages in the four of the rats that were tested. This does not follow along with previous research 
for clozapine with a training dose of 1.25 mg/kg, as Porter, et al. (2000) found that 
chlorpromazine did not produce substitution in clozapine-trained rats, although that study did not 
include a 2.0 mg/kg dose, and there was rate suppressing effects for all seven rats in that study at 
the 4.0 mg/kg dose of chlorpromazine. In the current study, there is a significant difference in 
responding when the clozapine trained rats were given chlorpromazine, but post-hoc analysis did 
not find that it occurred at any specific doses. 
Drug discrimination studies that have used 5.0 mg/kg of clozapine as the training drug, 
which has shown to be less sensitive to the differences between typical and atypical 
antipsychotics (Goudie and Taylor, 1998; Prus, et al., 2005), also found that chlorpromazine does 
not substitute for clozapine. Other studies have shown that clozapine will produce substitution in 
rats trained on chlorpromazine (Porter, et al. 1999), yet the substitution for clozapine trained rats 
testing chlorpromazine has not been symmetrical (Porter, et al., 2000; Prus, et al, 2005). 
These previous studies had both looked at two lever discrimination for clozapine trained 
rats, however, there is some evidence for rats substituting clozapine. In a three lever 
discrimination task, Porter et al. (2005) was able to get rats to discriminate 1.0 mg/kg 
chlorpromazine versus 5.0 mg/kg clozapine versus vehicle. This study found that chlorpromazine 
at the 4.0 mg/kg dose did partially generalized to clozapine. 
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Group 2: Methylene blue 
In the five rats that were tested, methylene blue was found to partially substitute at 7.5 
mg/kg for clozapine for four of the rats. While five of the rats had tested for methylene blue, 
three of experienced rate disrupting effects, and each of them had experienced it at a different 
dose. This study may be the first time methylene blue has been used a testing compound in a 
discriminative stimulus assay, but it’s not the first time that methylene blue has been compared 
to other APDs: Klamer, Engel, and Svensson (2004) had found that methylene blue at 50 mg/kg 
and 100 mg/kg dosages via IP reversed PPI of the acoustic startle response caused by 
phencyclidine in mice.  
Methylene blue has also been explored for anxiolytic and antidepressant properties. In 
rats that were subjected to an elevated plus maze, a preclinical assay designed to measure anxiety 
by watching how much time an animal spends in the open sections of the maze or the closed 
section of the maze, it was found the methylene blue had dose dependent effects. At low doses, 
7.5 mg/kg, 15 mg/kg, and 30 mg/kg via intravenous (IV) injection, the rats had spent a 
significantly more time in the open arms compared to baseline, which indicates these doses 
likely have anxiolytic properties, yet at 60 mg/kg via IV, the rats spent significantly more time in 
the enclosed arms compared to baseline, which may indicate anxiogenic effects. Additionally, 60 
mg/kg was found to cause a significant decrease in locomotor activity (Eroglu & Caglayan, 
1997). During the course of the current study, two of the rats were given a 60 mg/kg test 
sessions, but failed to respond when put in their operant chamber, so that dose was not given to 
the remaining rats. Due to the low dose of 7.5 mg/kg partially substituting for clozapine, it may 
be worth exploring even lower doses to see it increases drug lever responding, in addition to 
seeing if there are still selective rate disrupting effects for lower doses for some of the rats.  
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While there are many other APDs that generalize for clozapine in rats, there is also 
evidence for full substitution by the antihistamines cyproheptadine and promethazine, and the 
antidepressants, amitriptyline and mianserin for clozapine at the 5.0 mg/kg dose (Kelley & 
Porter, 1997). The tricyclic antidepressant imipramine has been found in some studies to 
partially substitute for clozapine in rats (Kelley & Porter, 1997), and not at all in other studies 
(Nielson, 1988). Methylene blue does have some antidepressant and anxiolytic properties 
(Eroglu & Çaglayan, 1997; Oz, et al., 2011), and despite being used in medicine for 100 years, 
little is known about the receptor binding profile of methylene blue, aside from it likely binding 
to GABAA receptors (Chen, Liu, Yang, Dillon, & Huang, 2017). The discriminative stimulus of 
clozapine relies on its complex binding profile which acts on a range of receptors. Previous drug 
discrimination studies have indicated that clozapine’s discriminative stimulus properties can be 
mediated by muscarinic, alpha1 andrenergic, or dopaminergic D2 antagonism (Porter, Prus, Vann, 
& Varvel, 2005), and more recently studies have implicated serotonergic 5-HT2A inverse 
agonism, and dopaminergic D4 antagonism (Prus, et al., 2016). This complex receptor binding 
affinity is likely what it has in common with the various antidepressants and antihistamines that 
have substituted for it by the animals of the previous drug discriminations, and possibly what it 
shares in common with methylene blue as well. 
Group 2: Quinacrine 
 In the four rats tested, quinacrine was not found to substitute for clozapine. Quinacrine 
falls under two chemical families, the phenothiazines, of which it shares three heterocyclic rings, 
and its antihelmintic properties (Swazey, 1974), and the quinolines, which looks chemically 
similar to phenothiazine but has two heterocyclic rings instead of three, which it shares 
antimalarial properties with, and includes other drugs such as quinine, chloroquine, and 
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mefloquine. The quinoline antimalarials have been found to be linked to depression, confused 
states, insomnia, anxiety, and delusions (Nevin & Croft, 2016). Quinacrine decreasing sensitivity 
to PPI in rats does help to provide further evidence to suggest that, aside from methylene blue, 
antimalarial drugs do not appear to have antipsychotic efficacy (Lee, et al., 2009). 
Malaria is a disease that is characterized by fever, loss of energy, emesis, and in more 
extreme cases, seizures and coma. Malariotherapy had also been used as a treatment for 
schizophrenia, among other conditions, by use of fever, seizures, and coma, as treatments for 
psychosis, in the pre-chlorpromazine era (Freitas, et al., 2014). Malriotherapy had been so 
effective at treating individuals with neurosyphilis and schizophrenia, Julius Wagner-Jauregg 
had won the 1927 Nobel Prize in medicine for developing the treatment (Tsay, 2013). To say that 
malaria induced sedative like effects, while quinacrine and other quinoline antimalarials reduce 
the effects of Malaria by inducing agitation, would be a gross oversimplification of the treatment 
of the disease, but one that follows along the logic of early scientific merit.  
Limitations 
 This study was limited by several factors. Despite chlorpromazine being described as 
having a robust discriminative stimulus, the drug was not able to be established as a 
discriminative stimulus without great difficulty, or reliability. It cannot be ruled out that the 
effects of several phase changes likely affected how the rats will generalize novel drugs. The 
clozapine trained rats despite having more readily acquired the discrimination, had their share of 
difficulties as well, such as the chlorpromazine partially substituting at the higher doses for 
clozapine, despite not having a precedent for that in previous literature in a two lever 
discrimination procedure. This illustrates how the drug discrimination paradigm is affected by 
individual components of a compound cue, and while it may be useful for exploring similarities 
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in the subjective effects of drugs due to similarity in pharmacological profile, but does not 
elucidate the specific mechanism of action of these drugs. Drug discrimination can be useful in 
determining behavioral effects of drugs, however there is not yet it has not been determined the 
link between the discriminative stimulus effects of antipsychotic drugs, and their therapeutic 
efficacy. 
 Methylene blue having a partial generalization to clozapine is of interest in this particular 
study, it should also be noted that to confirm that these drugs do indeed have similar receptor 
activity, positive and negative controls should be used to confirm the findings. Using another 
atypical antipsychotic, such as olanzapine that has previously been shown to generalize to 
clozapine (Prus, et al., 2005), would confirm that drug lever responses are due to similarity of 
receptor activity. A negative control could be established by a drug with known pharmacological 
dissimilarity to clozapine, such as amphetamine, which has been shown to have its 
discriminative stimulus effects antagonized by clozapine, among other antipsychotics (Nielsen & 
Jepsen, 1985) would help to confirm that lever pressing on drug lever was not due to 
dissimilarity from the control condition. 
 Finally, if a drug such as methylene blue is indeed found to have therapeutic effects in the 
treatment of schizophrenia, or other illnesses, it may not be of much value to patients that 
experience the drugs unpleasant subjective effects. Individuals with schizophrenia report higher 
levels of dissatisfaction and perceived adverse effects with typical antipsychotics compared to 
that of atypical antipsychotics (Hellewell, 2002). This should serve as a reminder to the point 
that new drug treatment should not be worse than the illness. 
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Future research 
 This study has several findings that could be useful in the development of future research. 
Methylene blue partially substituting for clozapine is noteworthy, as there are a number of 
different experiments that can be performed to further explore antipsychotic, antidepressant, or 
anxiolytic value of methylene blue. Additionally, it may be of interest to examine the 
psychoactive effects of the different antimalarial drugs, as their mechanism of action is not well 
understood, and if quinacrine or other quinoline antimalarials do exert adverse psychiatric effects 
that may be worth exploring as a putative deficit inducer. 
Conclusions 
 The present study sought to further explore the discriminative stimulus properties of 
current APDs. Despite being well characterized in the literature, antipsychotic medicine is far 
from perfect, as current antipsychotic medicine only treats symptoms of schizophrenia, and 
asymmetrically treats positive symptoms more so than negative symptoms. Many individuals 
that suffer from schizophrenia also struggle with the side effects of the medications that they 
have to take. Finding the right medication for each individual can also be quite difficult, as not 
all antipsychotics work effectively in all individuals. It is important for us to find the treatment 
for the right person. The use of methylene blue, may not be right treatment for all people who 
experience psychosis, but it may have therapeutic value for some. The findings of this study 
suggest methylene blue may exhibit antipsychotic-like effects, further research is needed in 
models that are specifically predictive of antipsychotic activity. 
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Until a treatment is discovered that is more effective than the drugs that we have 
available today, there should be a continued effort to find new drugs, and drug discrimination 
can be an effective tool for exploring the pharmacological action of new drugs.  
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Figure 1: Mean % chlorpromazine lever responding for two lever training in rats trained to 
discriminate chlorpromazine from vehicle. The x-axis indicating the number of sessions for the 
drug and vehicle testing, and the y-axis indicates the percent of drug lever responding. The 
number in parenthesis indicates the number of rats that had yet to meet criteria, otherwise the 
number of rats is equal to N. The dotted lines across the x-axis indicating phase changes: the first 
one indicating change in training dose from 1.0 mg/kg via IP to 2.0 mg/kg via IP; second 
indicating change in route of administration from IP to SC; third indicating change from 2.0 
mg/kg via SC to 1.0 mg/kg via SC; and fourth indicating 1.0 mg/kg SC to 0.5 mg/kg SC.   
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Figure 2: Mean % clozapine lever responding for two lever training in rats trained to 
discriminate 1.25 mg/kg clozapine from vehicle. The x-axis indicating the number of sessions for 
the drug and vehicle testing, and the y-axis indicates the percent of drug lever responding. The 
number in parenthesis indicates the number of rats that had yet to meet criteria, otherwise the 
number of rats is equal to N. 
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Figure 3: Generalization results for clozapine in rats trained to discriminate 1.25 mg/kg 
clozapine from vehicle in a two lever drug discrimination task. Mean percent drug lever 
responding is shown in the upper panel, and mean responses per second are shown in the lower 
panel. The dashed line at 80% indicates full generalization to the drug lever. Prior to 
generalization testing, control tests were conducted with the clozapine training dose and vehicle. 
Rats with response rates below 5 responses per minute in a given test session were not included 
in the % drug lever data. 
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Figure 4: Generalization results for chlorpromazine in rats trained to discriminate 1.25 mg/kg 
clozapine from vehicle in a two lever drug discrimination task. Mean percent drug lever 
responding is shown in the upper panel, and mean responses per second are shown in the lower 
panel. The dashed line at 80% indicates full generalization to the drug lever. Prior to 
generalization testing, control tests were conducted with the chlorpromazine training dose and 
vehicle. Rats with response rates below 5 responses per minute in a given test session were not 
included in the % drug lever data. 
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Figure 5: Generalization results for methylene blue in rats trained to discriminate 1.25 mg/kg 
clozapine from vehicle in a two lever drug discrimination task. Mean percent drug lever 
responding is shown in the upper panel, and mean responses per second are shown in the lower 
panel. The dashed line at 80% indicates full generalization to the drug lever. Prior to 
generalization testing, control tests were conducted with the methylene blue training dose and 
vehicle. Rats with response rates below 5 responses per minute in a given test session were not 
included in the % drug lever data. 
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Figure 6: Generalization results for quinacrine in rats trained to discriminate 1.25 mg/kg 
clozapine from vehicle in a two lever drug discrimination task. Mean percent drug lever 
responding is shown in the upper panel, and mean responses per second are shown in the lower 
panel. The dashed line at 80% indicates full generalization to the drug lever. Prior to 
generalization testing, control tests were conducted with the quinacrine training dose and vehicle. 
Rats with response rates below 5 responses per minute in a given test session were not included 
in the % drug lever data. 
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